Thesis icon

Thesis

Autoinhibition releasing provides a platform for developing p21-activated kinase-1 (PAK1) activators for hypertrophic heart diseases

Abstract:

Kinase activators have attracted great attention in recent years due to their therapeutic benefits in pathological conditions. However, the pursuit of kinase activators has encountered limited success, emphasising the importance of a strategic approach to define specific targeted sites. Our focus centres on p21activated kinase-1 (PAK1), which is important in maintaining cellular homeostasis and enhancing cardiomyocyte adaptability to stress. Numerous studies have highlighted the therapeuti...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Pharmacology
Role:
Author

Contributors

Institution:
University of Oxford
Division:
MSD
Department:
Pharmacology
Role:
Supervisor
ORCID:
0000-0002-0928-341X


DOI:
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford


Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP